# The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

Study · id `cardio:ct-nct05464095` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05464095](<https://clinicaltrials.gov/study/NCT05464095>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05464095

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05464095. Randomized; double masking; primary purpose treatment. Start 2023-01-01 (actual); primary completion 2027-05-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05464095, source copy `cardio:ctgov-nct05464095-2026-08-20`, retrieved 2026-10-31)
- Started: 2023-01-01 (actual) (ClinicalTrials.gov record NCT05464095, source copy `cardio:ctgov-nct05464095-2026-08-20`, retrieved 2026-10-31)
- Primary completion: 2027-05-03 (anticipated) (ClinicalTrials.gov record NCT05464095, source copy `cardio:ctgov-nct05464095-2026-08-20`, retrieved 2026-10-31)
- Completion: 2027-08-31 (anticipated) (ClinicalTrials.gov record NCT05464095, source copy `cardio:ctgov-nct05464095-2026-08-20`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05464095, source copy `cardio:ctgov-nct05464095-2026-08-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05464095-2026-08-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
- Acronym: MOVE PAH)
- Condition: Pulmonary Arterial Hypertension
- Intervention (Device): mHealth Intervention
- Intervention (Device): Usual Care
- Lead sponsor: Vanderbilt University Medical Center
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Vanderbilt University Medical Center (`cardio:org-vanderbilt-university-medical-center`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 9f5c7852b7824717dd5fae78580e3df3b1002732fdb5d97ccd646ba7f475fd7d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
